📊 SLDB Key Takeaways
Is Solid Biosciences Inc. (SLDB) a Good Investment?
Solid Biosciences exhibits critical financial distress with collapsing revenue (-40.6% YoY), unsustainable operating losses of $179.2M against only $8.1M in revenue, and severe cash burn of $157.4M annually that will exhaust the company's $59.9M cash reserve in approximately 4 months. Without immediate capital raise or dramatic operational restructuring, the company faces existential liquidity crisis.
Why Buy Solid Biosciences Inc. Stock? SLDB Key Strengths
- Strong balance sheet with $180M stockholders' equity and zero long-term debt, preserving financial flexibility for capital raises
- Excellent liquidity ratios (6.14x current/quick ratio) ensuring near-term operational continuity
- EPS improved 35% YoY, showing some moderation in per-share losses despite deteriorating operations
SLDB Stock Risks: Solid Biosciences Inc. Investment Risks
- Critical cash runway: $59.9M cash against $156.3M annual operating burn leaves only 4-5 months of liquidity at current rate
- Revenue collapse of 40.6% YoY signals severe business deterioration, failed product commercialization, or pipeline failure
- Extreme operating losses (-$179.2M) with operating margin of -2214% indicate fundamental business model dysfunction and unsustainable cost structure
Key Metrics to Watch
- Quarterly cash balance and burn rate trajectory to determine capital raise timing and dilution magnitude
- Revenue stabilization and new product/pipeline catalysts to validate business viability
- Operating expense reduction initiatives and path to operating cash flow positive status
Solid Biosciences Inc. (SLDB) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 6.14x current ratio provides a solid financial cushion.
SLDB Profit Margin, ROE & Profitability Analysis
SLDB vs Healthcare Sector: How Solid Biosciences Inc. Compares
How Solid Biosciences Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Solid Biosciences Inc. Stock Overvalued? SLDB Valuation Analysis 2026
Based on fundamental analysis, Solid Biosciences Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Solid Biosciences Inc. Balance Sheet: SLDB Debt, Cash & Liquidity
SLDB Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Solid Biosciences Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-3.06 indicates the company is currently unprofitable.
SLDB Revenue Growth, EPS Growth & YoY Performance
SLDB Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2020 | N/A | -$21.2M | N/A |
| Q2 2020 | N/A | -$19.0M | N/A |
| Q1 2020 | N/A | -$26.7M | N/A |
| Q3 2019 | N/A | -$19.0M | N/A |
| Q2 2019 | N/A | -$18.0M | N/A |
| Q1 2019 | N/A | -$15.9M | N/A |
| Q3 2018 | N/A | -$13.5M | N/A |
| Q2 2018 | N/A | -$11.3M | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Solid Biosciences Inc. Dividends, Buybacks & Capital Allocation
SLDB SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Solid Biosciences Inc. (CIK: 0001707502)
📋 Recent SEC Filings
❓ Frequently Asked Questions about SLDB
What is the AI rating for SLDB?
Solid Biosciences Inc. (SLDB) has an AI rating of STRONG SELL with 92% confidence, based on fundamental analysis of SEC EDGAR filings.
What are SLDB's key strengths?
Claude: Strong balance sheet with $180M stockholders' equity and zero long-term debt, preserving financial flexibility for capital raises. Excellent liquidity ratios (6.14x current/quick ratio) ensuring near-term operational continuity.
What are the risks of investing in SLDB?
Claude: Critical cash runway: $59.9M cash against $156.3M annual operating burn leaves only 4-5 months of liquidity at current rate. Revenue collapse of 40.6% YoY signals severe business deterioration, failed product commercialization, or pipeline failure.
What is SLDB's revenue and growth?
Solid Biosciences Inc. reported revenue of $8.1M.
Does SLDB pay dividends?
Solid Biosciences Inc. does not currently pay dividends.
Where can I find SLDB SEC filings?
Official SEC filings for Solid Biosciences Inc. (CIK: 0001707502) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is SLDB's EPS?
Solid Biosciences Inc. has a diluted EPS of $-1.99.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is SLDB a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Solid Biosciences Inc. has a STRONG SELL rating with 92% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is SLDB stock overvalued or undervalued?
Valuation metrics for SLDB: ROE of -96.8% (sector avg: 15%), net margin of -2,153.8% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy SLDB stock in 2026?
Our dual AI analysis gives Solid Biosciences Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is SLDB's free cash flow?
Solid Biosciences Inc.'s operating cash flow is $-156.3M, with capital expenditures of $1.2M. FCF margin is -1,945.2%.
How does SLDB compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -2,153.8% (avg: 12%), ROE -96.8% (avg: 15%), current ratio 6.14 (avg: 2).